Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 537 participants.

Also called NCT06354660

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 537 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06354660
Other papers using this trial's data
  • Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial Lancet (London, England), 2026-06-13 DOI, PubMed 42250575

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, India, Mexico, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06354660. Randomized; double masking; primary purpose treatment. Start 2024-04-10 (actual); primary completion 2026-01-22 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
Condition
Diabetes Type 2
Intervention (Drug)
Retatrutide
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct06354660
Content hash
54cd037a367ca3f9ce347ef0161817078c8dbe7beb771f2b69f94205d6249a7e